Skip to main content
. 2012 Jul 10;23(10):1043–1053. doi: 10.1089/hum.2012.041

FIG. 5.

FIG. 5.

EGFRvIII CAR vector-transduced glioblastoma patient T cells recognize EGFRvIII-expressing tumors. (A) PBLs from normal donor 6 and two glioblastoma (GBM) patients were transduced with anti-EGFRvIII vector and cocultured with U87 or U87-EGFRvIII cells followed by intracellular cytokine staining for IFN-γ. Shown are the resultant FACS dot blots for IFN-γ and CD8. The expression of the anti-EGFRvIII CAR in the patients' T cells was as shown in the FACS histograms plotted on the right (shaded histograms, isotype control). (B) Transduced T cells from part A (CAR+) were subject to an REP and, 14 days later, evaluated by IFN-γ Elispot assay. Shown are the stained well images (left) along with the quantitation of the number of IFN-γ-reactive spots (right). Phytohemagglutinin (PHA) was used as a nonspecific T-cell activator. UT, untransduced T cells.